Impact of medication adherence on absenteeism and short-term disability for five chronic diseases

Journal of Occupational and Environmental Medicine

Volumn 54, Issue 7, 2012, Pages 792-805

  Carls, Ginger S ^a,d   Roebuck, M Christopher ^b   Brennan, Troyen A ^b   Slezak, Julie A ^b,c   Matlin, Olga S ^b   Gibson, Teresa B ^a,d  

^a THOMSON REUTERS   (United States)

^b CVS Caremark   (United States)

^c Silverlink Communications   (United States)

^d IBM WATSON HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE ANTAGONIST; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; BILE ACID SEQUESTRANT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; INSULIN DERIVATIVE; MEGLITINIDE; METHYLXANTHINE DERIVATIVE; NICOTINIC ACID; NITRIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT; STEROID; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG; VASODILATOR AGENT;

ABSENTEEISM; ARTICLE; ASTHMA; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISABILITY; DYSLIPIDEMIA; FOLLOW UP; HEALTH INSURANCE; HYPERTENSION; PATIENT COMPLIANCE;

ABSENTEEISM; ASTHMA; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SICK LEAVE;

EID: 84863829175     PISSN: 10762752     EISSN: 15365948     Source Type: Journal    
DOI: 10.1097/JOM.0b013e31825463e9     Document Type: Article

References (38)

1. Gallup Healthways. The working population Gallup Healthways Well-Being Index. April 28th Hill Briefing; 2008. Available at: http://www.wellbeingindex. com. Accessed May 8, 2012.
2. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff. 2011;30:91-99.
3. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836-1841. (Pubitemid 44455165)
4. Gibson TB, Song X, Alemayehu B, et al. Cost-sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care. 2010;16:589-600.
5. Gibson TB, Mark TL, Axelsen K, Basur O, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006;12(Special Issue):SP11-SP19. (Pubitemid 46053391)
6. Sokol M, McGuigan K, Verbrugge RR, Epstein RS. Impact of medication adherence of hospitalization risk and healthcare cost. Med Care. 2005; 43:521-530. (Pubitemid 40847288)
7. Encinosa WE, Bernard D, Dor A. Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes. In: Dor A, ed. Pharmaceutical Markets and Insurance Worldwide. Advances in Health Economics and Health Services Research. Vol 22. Rockville,MD: Emerald Group Publishing Ltd; 2010:151-173.
8. Tan H, Sarawate C, Singer J, et al. Impact of asthma controller medications on clinical, economic and patient-reported outcomes. Mayo Clin Proc. 2009;84:675-684.
9. Stuart BC, Doshi JA, Terza JV. Assessing the impact of drug use on hospital costs. Health Serv Res. 44:128-144.
10. DeVol R, Bedroussian A. An Unhealthy America: The Economic Burden of Chronic Disease Charting a New Course to Save Lives and Increase Productivity and Economic Growth. Santa Monica, CA: Milken Institute; 2007.
11. Thomson Reuters. Detailed information on the MarketScan R Research Databases including a complete bibliography of published, peer-reviewed articles utilizing these data. Available at: http://thomsonreuters.com/products services/healthcare/healthcare products/a-z/marketscan research databases pharma/. Accessed December 1, 2010.
12. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care. 2008;46:1125-1133.
13. Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15:457-464.
14. Bureau of Labor Statistics. US Department of Labor. Employer costs for employee compensation-June 2011. Available at: www.bls.gov/ect. Accessed October 18, 2011.
15. US Department of Health and Human Services, Health Resources and Services Administration, Bureau of Health Professions. Area Resource File. US Department of Health and Human Services, Health Resources and Services Administration, Bureau of Health Professions, Rockville, MD; 2008.
16. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for usewith ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
17. Bureau of Labor Statistics. Medical Care Price Index All Urban Consumers. Series IDCUUR0000SAM.Available at:www.bls.gov/cpi.Accessed September 23, 2011.
18. Stata [computer program]. Release MP 11.1. College Station, TX: StataCorp LP; 2009.
19. Mullahy J. Specification and testing of some modified count data models. J Econom. 1986;33:241-365.
20. Terza JV, Bradford WD,Dismuke CE. The use of linear instrumental variables methods in health services research and health economics: A cautionary note. Health Serv Res. 2008;43:1102-1120. (Pubitemid 351623957)
21. Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. J Health Econ. 2008;27:531-543.
22. French MT, Popovici I. That instrument is lousy! In search of agreement when using instrumental variables estimation in substance use research. Health Econ. 2011;20:127-146.
23. GoldmanDP, JoyceGF, ZhengY. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298:61-69. (Pubitemid 47026771)
24. Dru OK, Schmittdiel JA, Dyer WT, et al. Mail-order pharmacy use and adherence to diabetes-related medications. Am J Manag Care. 2010;16:33-40.
25. Staiger D, Stock JH. Instrumental variables regression with weak instruments. Econometrica. 1997;65:557-586. (Pubitemid 127466159)
26. Stock JH, Wright JH, Yogo M. A survey of weak instruments and weak identification in generalized method of moments. J Bus Econ Stat. 2002;20:518-529.
27. Shea DG, Terza JV, Stuart BC, Briesacher B. Estimating the effects of prescription drug coverage for medicare beneficiaries. Health Serv Res. 2007;42:933-949. (Pubitemid 46699482)
28. Loeppke R, Haufle V, Jinnett K, et al. Medication adherence, comorbidities, and health risk impact on workforce absence and job performance. J Occup Environ Med. 2011;53:595-604.
29. Joshi AV, Madhavan SS, Ambegaonkar A, Smith M, Scott V, Dedhia H. Association of medication adherence with workplace productivity and healthrelated quality of life in patients with asthma. J Asthma. 2006;43:521-526. (Pubitemid 44567604)
30. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol. 2007;166:348-354. (Pubitemid 47216808)
31. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31:596-615.
32. Lynch WD, Markosyan K, Melkonian AK, Pesa J, Kleinman NL. Effect of antihypertensive medication adherence among employees with hypertension. Am J Manag Care. 2009;15:871-880.
33. Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med. 2004;46:398-412. (Pubitemid 38469017)
34. Wang PS, Beck A, Berglund P, et al. Chronic medical conditions and work performance in the health and work performance questionnaire calibration surveys. J Occup Environ Med. 2003;45:1303-1311. (Pubitemid 37541945)
35. Burton WN, Morrison A, Wertheimer AI. Pharmaceuticals and worker productivity loss: A critical review of the literature. J Occup Environ Med. 2003;45:610-621. (Pubitemid 36702677)
36. Goldfarb N, Weston C, Hatmann C, et al. Impact of appropriate pharmaceutical therapy for chronic conditions on direct medical costs and workplace productivity: A review of the literature. Dis Manag. 2004;7:61-75. (Pubitemid 38436643)
37. Williams SA, Wagner S, Kannan H, Bolge SC. The association between asthma control and health care utilization, work productivity loss and healthrelated quality of life. J Occup Environ Med. 2009;51:780-785.
38. Burton W, Morrison A, Maclean R, Ruderman E. Systematic reviewof studies of productivity loss due to rheumatoid arthritis. Occup Med. 2006;56:18-27. (Pubitemid 43103362)